Intellia Therapeutics, Inc.

NTLA · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$519-$481-$474-$268
Dep. & Amort.$10$9$8$7
Deferred Tax$0$0$0$9
Stock-Based Comp.$154$134$91$47
Change in WC$12-$52-$54-$23
Other Non-Cash-$6-$3$96$3
Operating Cash Flow-$349-$394-$333-$225
Investing Activities
PP&E Inv.-$6-$14-$58-$13
Net Acquisitions$0$0-$45-$3
Inv. Purchases-$936-$904-$429-$1,021
Inv. Sales/Matur.$1,067$887$648$486
Other Inv. Act.$0$0$45$0
Investing Cash Flow$126-$31$160-$551
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$177$120$566$694
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$9$11$17$43
Financing Cash Flow$186$130$583$737
Forex Effect$0$0$0$0
Net Chg. in Cash-$38-$295$410-$39
Supplemental Information
Beg. Cash$240$535$125$165
End Cash$203$240$535$125
Free Cash Flow-$355-$408-$392-$238
Intellia Therapeutics, Inc. (NTLA) Financial Statements & Key Stats | AlphaPilot